# SAREPTA THERAPEUTICS, INC. (SRPT) · Edgar & Edgarette company card

> Sarepta Therapeutics (SRPT) grew revenue 15.6% in FY2025 to $2.2 billion, operating margin -31.8% against a -3.8% median for pharmaceutical preparations, equity 34.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 873303 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SRPT) · [JSON](https://www.pops4.com/boards/company/SRPT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2.2B |
| Revenue growth, 1 year | 15.6% |
| Revenue growth per year | 33.0% |
| Operating margin | -31.8% (prior year 11.5%) |
| Net margin | -32.5% |
| Operating cash flow | −$205M |
| Capital spending | $102M |
| Free cash flow | −$307M |
| Cash | $801M |
| Long-term debt | $829M |
| Total assets | $3.3B |
| Total equity | $1.1B |
| Equity ÷ assets | 34.1% |
| Return on equity | -62.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.78 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -31.8% in FY2025
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $2.2B (FY2025), total debt $829.0M. Experience: revenue up 15.6% on the year, up 33.0% a year over 4 years; operating margin -31.8%, down from 11.5%. Soundness: equity 34.1% of assets, return on equity -62.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.3B and $3.1B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.1B to $3.5B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -31.8% against a -3.8% median; growth 15.6% against 13.7%.

Range logged 2026-09-24, receipt ada272f1adf1a6af, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-07-27 ([filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm))

## Recent filings

- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526449822/0001193125-26-449822-index.htm)
- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526449721/0001193125-26-449721-index.htm)
- 8-K · filed 2026-09-23 · 1.01 Entry into a Material Definitive Agreement · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526399416/0001193125-26-399416-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526335056/0001193125-26-335056-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526335003/0001193125-26-335003-index.htm)
- 8-K · filed 2026-07-27 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/873303/000119312526316995/0001193125-26-316995-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000873303.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=873303

## Cite

POPS4, Edgar & Edgarette: SAREPTA THERAPEUTICS, INC. (SRPT) company card, from the company's own SEC filings, accessed 2026-11-08, https://www.pops4.com/boards/company/SRPT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.